Johnson & Johnson stock touched a fresh all-time high of $251.76 on Thursday, June 26, before pulling back slightly to trade around $251.18 — still just 0.97% below that peak. The move puts JNJ’s 1-year total return at 65.12%, with a market cap of $604.8 billion.
The rally comes the same day Guggenheim lifted its price target on JNJ to $270, up from $266, while holding its Buy rating. The firm also named JNJ a top pick among large-cap biopharmaceutical companies.
Guggenheim is penciling in Q2 2026 revenues of $25.48 billion and earnings per share of $2.87. Both figures sit above the current Wall Street consensus of $24.96 billion in revenue and $2.85 EPS.
The price target increase was fueled by stronger-than-expected prescription trends for three key drugs: Tremfya, Caplyta, and Erleada. All three came in ahead of Guggenheim’s internal estimates.
The firm flagged that prescription data for two newer launches — Icotyde and Inlexzo — are not yet reliable enough to factor in. Analysts will be watching those closely once data matures.
Guggenheim expects the earnings call on July 15 to center on Tremfya volume growth, the Icotyde launch, the multiple myeloma portfolio, Caplyta, and Spravato.
JNJ has raised its dividend for 55 consecutive years, which continues to make it a go-to name for income-focused investors.
Away from the stock, JNJ announced an investment of more than $1 billion into its Jacksonville, Florida operations. The money is earmarked for expanding manufacturing, packaging, and distribution capacity for its Vision business, with a focus on ACUVUE contact lenses.
The company also expanded U.S. availability of its TECNIS PureSee intraocular lens, used in cataract surgery. On the clinical side, JNJ reported positive Phase 2/3 results for Imaavy in patients with warm autoimmune hemolytic anemia.
Not everything is smooth sailing. A Los Angeles jury found JNJ liable for mesothelioma in the case of Maria Lozano, awarding her family $32 million. The case ties back to asbestos-contaminated talc in JNJ’s baby powder — a legal overhang the company has dealt with for years.
InvestingPro analysis currently flags the stock as slightly overvalued at these levels, even with the strong momentum behind it.
The post Johnson & Johnson (JNJ) Stock Breaks Records — Here’s What’s Behind the Move appeared first on CoinCentral.
